Skip to main content

Table 4 Multivariate linear regression analysis of factors associated with the change in log-UACR

From: Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study)

  B SE β P value
Change in morning home SBP (mmHg) 0.01626 0.00733 0.26330 0.0305
Diabetes duration (year) − 0.02156 0.01236 − 0.24438 0.0867
Fasting blood sugar (mg/dL) − 0.00332 0.00219 − 0.17868 0.1353
Change in office SBP (mmHg) 0.00668 0.00482 0.17351 0.1712
HbA1c (%) − 0.22415 0.16215 − 0.18777 0.1723
WBC (/mm3) 0.00005302 0.00005094 0.14462 0.3025
Change in body weight (kg) 0.04017 0.04919 0.11133 0.4176
Change in HbA1c (%) − 0.04314 0.16195 − 0.03561 0.7909
Change in d-ROMs (CARR U) 0.00057766 0.00244 0.03157 0.8141
  1. Adjusted R2 = 0.1942, P = 0.01. Variables included in the model were changes in morning home SBP, office SBP, body weight, HbA1c, and d-ROMs, and baseline values of diabetes duration, fasting blood sugar, HbA1c, and WBC
  2. B regression coefficient, SE standard error, β standardized regression coefficient, SBP systolic blood pressure, HbA1c glycated hemoglobin, WBC white blood cell, d-ROMs diacron-reactive oxygen metabolites